Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Hyatt Hotels Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Hyatt Hotels Corporation trades at $172.22 (market cap $16.03B). The key difference: Hyatt Hotels Corporation is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.35% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | H | |
|---|---|---|
Market Cap | $9.39B | $16.03B |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $202.09 |
52-Week Low | $241.71 | $135.42 |
Enterprise Value | $9.14B | $19.93B |
Dividend Yield | — | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Hyatt Hotels Corp (H) trades at $177.71, down 0.65% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings beats in Q2 2026 and a raised RevPAR outlook highlight operational momentum, but high valuation ratios and a negative net income in 2025 pose concerns. The stock is near its 52-week high of $206.86, with support at $176 and resistance at $180.
The outlook is cautious; while fee growth and travel demand support expansion, the stock's rich valuation and debt levels warrant patience. Risks include regional weakness and project delays. Analysts maintain a mixed consensus with a $201 price target, suggesting limited near-term upside amid balanced investor sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
